JP2023539626A5 - - Google Patents

Info

Publication number
JP2023539626A5
JP2023539626A5 JP2023513706A JP2023513706A JP2023539626A5 JP 2023539626 A5 JP2023539626 A5 JP 2023539626A5 JP 2023513706 A JP2023513706 A JP 2023513706A JP 2023513706 A JP2023513706 A JP 2023513706A JP 2023539626 A5 JP2023539626 A5 JP 2023539626A5
Authority
JP
Japan
Prior art keywords
mmp
immune cells
nucleic acid
pharmaceutical composition
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513706A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539626A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/047889 external-priority patent/WO2022047119A1/en
Publication of JP2023539626A publication Critical patent/JP2023539626A/ja
Publication of JP2023539626A5 publication Critical patent/JP2023539626A5/ja
Pending legal-status Critical Current

Links

JP2023513706A 2020-08-28 2021-08-27 線維症及び炎症のための修飾免疫細胞 Pending JP2023539626A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063072046P 2020-08-28 2020-08-28
US63/072,046 2020-08-28
PCT/US2021/047889 WO2022047119A1 (en) 2020-08-28 2021-08-27 Modified immune cells for fibrosis and inflammation

Publications (2)

Publication Number Publication Date
JP2023539626A JP2023539626A (ja) 2023-09-15
JP2023539626A5 true JP2023539626A5 (cg-RX-API-DMAC7.html) 2024-09-04

Family

ID=80354009

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513706A Pending JP2023539626A (ja) 2020-08-28 2021-08-27 線維症及び炎症のための修飾免疫細胞

Country Status (10)

Country Link
US (1) US20230321144A1 (cg-RX-API-DMAC7.html)
EP (1) EP4204555A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023539626A (cg-RX-API-DMAC7.html)
KR (1) KR20230090314A (cg-RX-API-DMAC7.html)
CN (1) CN116075589A (cg-RX-API-DMAC7.html)
AU (1) AU2021331368A1 (cg-RX-API-DMAC7.html)
CA (1) CA3192646A1 (cg-RX-API-DMAC7.html)
IL (1) IL300671A (cg-RX-API-DMAC7.html)
MX (1) MX2023002411A (cg-RX-API-DMAC7.html)
WO (1) WO2022047119A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250075643A (ko) 2022-09-27 2025-05-28 레졸루션 쎄라퓨틱스 리미티드 치료용 대식세포
CN115786270A (zh) * 2022-12-01 2023-03-14 鲲石生物科技(深圳)有限公司 工程化的巨噬细胞及其在治疗纤维化疾病中的应用
CN115590880A (zh) * 2022-12-01 2023-01-13 鲲石生物科技(深圳)有限公司(Cn) 工程化的巨噬细胞联用在治疗纤维化疾病中的应用
CN116699116A (zh) * 2023-06-14 2023-09-05 河南省人民医院 检测嗜碱性粒细胞cd284表达水平的物质的应用
CN117030580B (zh) * 2023-09-15 2024-07-16 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) LDNs在坏死性小肠结肠炎诊断中的应用
CN122270550A (zh) 2023-09-27 2026-06-23 分解治疗有限公司 治疗性巨噬细胞
WO2025189163A2 (en) * 2024-03-08 2025-09-12 Carisma Therapeutics Inc. Modified immune cells for fibrosis and inflammation
WO2025202287A1 (en) 2024-03-26 2025-10-02 Resolution Therapeutics Limited Method of producing macrophages

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2183752T3 (es) * 1999-09-17 2005-07-16 Tgt Laboratories, S.A. De C.V. Vectores adenovirales recombinantes y su utilizacion en el tratamiento de la cirrosis de higado.
AU2003224950B2 (en) * 2002-04-09 2006-09-14 Biogen Ma Inc. Methods for treating tweak-related conditions
EP2549986B1 (en) * 2010-03-24 2019-10-30 Northeastern University Multi-compartmental macrophage delivery
EP3299453B1 (en) * 2016-09-23 2019-05-08 Xcell Medical Solutions, S.L. Cell therapy with polarized macrophages for tissue regeneration
US20210100837A1 (en) * 2017-12-14 2021-04-08 The University Of Chicago Treatment of fibrosis with genetically-engineered macrophages
WO2019238022A1 (en) * 2018-06-11 2019-12-19 Chineo Medical Technology Co., Ltd. Modified immune cells and uses thereof
WO2020160217A1 (en) * 2019-02-01 2020-08-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Microenvironment sensors to regulate engineered gene expression
CN111544585B (zh) * 2019-02-11 2024-12-27 北京卡替医疗技术有限公司 一种可助推免疫细胞在体内扩增的佐剂
US20250051749A1 (en) * 2021-12-24 2025-02-13 Toolgen Incorporated Novel promoter and use thereof
CN120035671A (zh) * 2023-05-11 2025-05-23 四川至善唯新生物科技有限公司 工程化的肝脏特异性核心启动子及其应用

Similar Documents

Publication Publication Date Title
US10918738B2 (en) Method of treating type I diabetes using an AAV vector encoding uracortin 2
JP5546453B2 (ja) 脂肪肝疾患の治療におけるインターロイキン−22の使用
EP2142206B1 (en) SDF-1 for use in the treatment of ischemic peripheral vascular disorders
US6383785B1 (en) Self-enhancing, pharmacologically controllable expression systems
US20040161412A1 (en) Cell-based VEGF delivery
JP2002502608A (ja) 血管新生促進因子である血管内皮細胞成長因子:vegfの変異体
JP2016019524A (ja) ハイブリッドユビキチンプロモーターを含む発現ベクター
JP2025121920A (ja) 完全ヒト翻訳後修飾抗体による治療剤
JPH04502406A (ja) ヒトdnアーゼ
WO2015150914A2 (en) Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunction and congestive heart failure
JP2002540175A (ja) 糖尿病及び肥満症の経口遺伝子治療
US20070020237A1 (en) Glucose inducible insulin expression and methods of treating diabetes
JP5269411B2 (ja) 幹細胞をホーミングさせるためのccrリガンド
JP2022513379A5 (cg-RX-API-DMAC7.html)
JPWO2022186282A5 (cg-RX-API-DMAC7.html)
WO2024213660A1 (en) Inflammation-inducible promoters
US20240307556A1 (en) Compositions and methods for reverse gene therapy
MXPA04007934A (es) Microorganismo envuelto.
De Young et al. 186 Modulation of vascular cell plasminogen activation by gene transfer In Vitro
Ke et al. 185 Rapid and efficient site-directed mutagenesis by single-tube ‘megaprimer’PCR method
Simon et al. 187 Adenovirus-mediated transfer of urokinase-type plasminogen activator genes to the lungs of mice upregulates plasminogen activator activity
Cyclohydrolase et al. 1111. Prolonged T 1. Prolonged T 1. Prolonged Transgene Expression in the ransgene Expression in the ransgene Expression in the Arterial Wall Using a Helper-Dependent all Using a Helper-Dependent all Using a Helper-Dependent Adenoviral V Adenoviral V Adenoviral Vector
JPH03123735A (ja) 悪性腫瘍治療剤